Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Overview
Date Founded

2001

Headquarters

784 Memorial Drive, Cambridge, MA, 02139, USA

Type of Company

Public

Employees (Worldwide)

22

Industries

Biotechnology
Pharmaceuticals

Company Description

Infinity is an innovative drug discovery and development company dedicated to discovering, developing and delivering to patients best-in-class medicines for diseases with significant unmet need. We believe that our small molecule discovery and development capabilities, strategic alliances, team of highly experienced management and scientists, and corporate culture form the basis of our potential long-term competitive advantage in seeking to deliver best-in-class medicines to patients

Website
Contact Data
Trying to get in touch with decision makers at Infinity Pharmaceuticals, Inc.? Subscribe today to access their professional contact information.
Executives & Employees

Chair & Chief Executive Officer

President & Treasurer

Vice President, General Counsel & Secretary

Senior Vice President & Chief Scientific Officer

Executive Vice President & Chief Medical Officer

Senior Vice President, Global Affairs

Vice President, Global Medical Affairs

Owner

Board of Directors

Chair & Chief Executive Officer at Infinity Pharmaceuticals, Inc.

Former Partner at Venrock Associates

Executive Vice President & Chief Operating Officer at Vertex Pharmaceuticals, Inc.

Managing Director at Bay City Capital LLC

Former Vice President-Global Market Access at Schering-Plough Corporation

Chairman at Real Endpoints LLC

Co-Founder at Karyopharm Therapeutics, Inc.

Former General Manager at Celera Corp.

Paths to Infinity Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Infinity Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Ghost Tree Capital LLC is a hedge fund manager located in New York City.

Details Hidden

Mont Blanc Capital Management AG is a private company headquartered in Zurich,, with subsidiaries in that country, that provides investment advice. The firm was founded in 2005 by Jens Biertumpel. Bross Ulrich is currently the CEO of the company.

Recent Transactions
Details Hidden

Infinity Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Infinity Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Infinity Pharmaceuticals, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Auditor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Managing Director

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Publicist

Senior Vice President at Stern Investor Relations, Inc.

Clients

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Key Stats and Financials As of 2017
Market Capitalization
$112M
Total Enterprise Value
$51M
Earnings Per Share
$-0.83
Five Year Compounded Annual Growth Rate Of Revenue
-33.78%
Three Year Compounded Annual Growth Rate Of Revenue
-66.87%
EBITDAMargin
-578.83%
Enterprise Value Sales
8.5x
Total Debt
$6M
EBITDA
$-34.7M
Debt TEV
0.12x
TEVNet Income
-1.22x
Net Profit
$-41.8M
Revenue
$6M
Total Equity
$47.7M
Non-Profit Donations & Grants
Suppliers
Takeda Pharmaceutical Co., Ltd. Chemicals | Tokyo, TY

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Bristol-Myers Squibb Company Medical Support Services | Princeton, NJ

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - WASHINGTON, DC

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Amgen, Inc. Biotechnology - Wilmington, DE

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.